bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Patient Education

  • Educate patient about the nature of the chronic bronchitis (the progressive nature and its potential impact on future lifestyle and function)
  • Review with the patient the signs of onset of infection (eg increased purulence, viscosity or volume of secretions) that should be treated early
  • Discuss measures that may limit the spread of viral infections (eg hand washing)
  • Encourage patients to exercise regularly
    • Although not accompanied by measurable improvement in lung function, it will increase exercise tolerance and improve the patient’s sense of well-being

Lifestyle Modification

Smoking Cessation

  • A discussion of smoking behavior and the setting of a specific cessation date should be part of every physician-patient encounter
  • Patients presenting with AECB should be encouraged to stop smoking since it is the most effective way to reduce the risk of future morbidity from chronic bronchitis
  • It can lead to dramatic symptomatic benefits for patients with chronic bronchitis eg stopping cough in 94-100%; when coughing stops, it can occur in as quickly as 4 weeks in 54% of patients

Reduction/Elimination of Irritants

  • Reduction or elimination of any source of irritants that may worsen lower airway inflammation
    • Includes environmental pollutants (eg dust, pollutants and second-hand smoke) and occupational irritants
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.